Sam Altman, Valley VCs Bet $48 Million on Blood-Testing Startup - Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world Americas+1 212 318 2000 EMEA+44 20 7330 7500 Asia Pacific+65 6212 1000 Years after Theranos, Vital Biosciences wants to prove Silicon Valley really can disrupt blood testing. Listen 5:18 Vital Biosciences Inc. plans to unveil new technology on Monday that it says can use a few drops of blood for 50 lab-grade tests in 20 minutes. The idea will give cold sweats to any investor familiar with Theranos Inc. That company, too, aimed to run large numbers of tests on small amounts of blood. It didn’t work, and its founder, Elizabeth Holmes, is currently serving 11 years in prison for fraud after the company rode a $9 billion valuation down to zero. Vital Biosciences and its backers are aware of the parallels. “In some ways, it makes it more intriguing,” said investor Lachy Groom. On Monday, the startup

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world Americas+1 212 318 2000 EMEA+44 20 7330 7500 Asia Pacific+65 6212 1000 Years after Theranos, Vital Biosciences wants to prove Silicon Valley really can disrupt blood testing. Listen 5:18 Vital Biosciences Inc. plans to unveil new technology on Monday that it says can use a few drops of blood for 50 lab-grade tests in 20 minutes. The idea will give cold sweats to any investor familiar with Theranos Inc.